DigestRedComo funciona
Red
/
Empresas
Bo
No verificado

Boehringer Ingelheim Limited

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

39 Comunicados de prensa

Ver todos los comunicados de prensa
26/02/2026
Farmacéutica
Medicina Salud Bienestar
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
27/01/2026
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
27/01/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
13/01/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
12/01/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
19/12/2025
Farmacéutica
Medicina Salud Bienestar
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
28/11/2025
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim announces appointment to Board of Managing Directors
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
04/11/2025
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
29/10/2025
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0